Logout Login Cart iconShop
Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "【Order On Telegram: @Chem2Door】Where To Buy Lunesta In San Diego,.7093"

Looking for quality documents?
publications icon
KB12006 SoloVPE Software Security Configuration Article
external link icon
Repligen Reports First Quarter 2020 Financial Results and Updates Full Year 2020 Financial Guidance
Reports record quarterly revenue of $76.1 million
Overall revenue grew 25% year-over-year, with organic growth of 16% Strong order load through first four months WALTHAM, Mass., May 06, 2020 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter ended March 31, 2020. Provided in this press release are financial highlights for the quarter, updates to our financial guidance for the year 2020 and access information for today’s webcast and conference call. Tony J. Hunt, President and Chief Executive Officer said, “I’m really pleased with our flexibility and performance during the first quarter, while adapting to the challenging economic environment. We exceeded our financial goals, reporting record quarterly revenue and organic growth of 16% backed by strong order demand. The story of the quarter was the continued momentum at gene therapy accounts and
corporate icon
Protein Concentration (A280)
Challenge: Manual concentration checks introduce variability and slow down release timelines. Our Solution: FlowVPX and SoloVPE PLUS offer rapid, dilution-free quantification at every stage—from UF/DF to final fill.
external link icon
Repligen Corporation Announces Agreement to Acquire Process Analytics Innovator C Technologies and Reports Preliminary First Quarter 2019 Financial Results
Proposed acquisition establishes a key franchise for Repligen in the rapidly growing Process Analytics segment of bioprocessing
Adds a market leader in protein concentration measurement with proprietary and differentiated spectroscopy technology Complements and advances our systems strategy in Chromatography and Filtration C Technologies is expected to contribute approximately $16-$17 million in revenue and be accretive to Repligen’s adjusted earnings per share in 2019 Repligen reports preliminary first quarter 2019 financial results, highlighted by 35%-37% year-over-year organic growth WALTHAM, Mass., April 26, 2019 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a definitive agreement to acquire privately-held C Technologies, Inc. for approximately $240 million, comprised of $192 million in cash plus $48 million in Repligen common stock. C Technologies
external link icon
Repligen to Present at the Lazard Capital Markets 7th Annual Healthcare Conference Wednesday, November 17th, 2:45 p.m. EST
external link icon
Repligen to Present at the Merriman Curhan Ford 6th Annual Investor Summit Tuesday, November 10th, 1:40 p.m. EST
publications icon
KB16008 SoloVPE Software V3 Security Configuration Article
publications icon
DOC0242 ConfiRM Slope Reference Materials Specification Sheet
news icon
New Affinity Resin for COVID-19 Vaccine Purification
corporate icon
Seed Train Intensification
Seed train intensification aims to generate ultra high-density cell cultures at optimal points during cell expansion using a robust cell retention device prior to the inoculation of the production bioreactor.
Close modal

A new look. A better way to explore Repligen.

We’ve redesigned Repligen.com to help you find the right solutions faster, with greater clarity and less effort.

Find what you need faster
Get to the right information with quicker site speed

Explore the site with ease
Navigate easily with an intuitive, simple site structure

Access product details instantly
Find products and resources faster, in fewer clicks

Get support when you need it
Connect with our team when you need support